New biosimilar aims to match keytruda in melanoma fight
Disease control
Ongoing
This study compares FYB206, a biosimilar (a very similar copy) of the cancer drug Keytruda, to the original Keytruda in 96 adults with stage IIB/IIC or III melanoma that has been completely removed by surgery. The goal is to see if FYB206 stays in the body the same way as Keytrud…
Phase: PHASE1 • Sponsor: Formycon AG • Aim: Disease control
Last updated May 11, 2026 20:52 UTC